Anatomic Pathology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Technique, By Application, By End-User By Region & Competition, 2021-2031F

The global anatomic pathology market is projected for significant growth, expanding from USD 36.09 billion in 2025 to USD 57.21 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 7.98%. This sector involves the microscopic study of tissues and cells to understand disease progression and inform treatment choices. Growth is largely fueled by an increasing worldwide prevalence of chronic diseases and an aging population, both of which drive a higher demand for biopsy procedures. This upward trend is further bolstered by a stronger emphasis on early detection and proactive healthcare strategies. For instance, the American Cancer Society anticipates around 2 million new cancer diagnoses in the United States in 2025, underscoring the vital role of precise pathological assessment.

A substantial obstacle to the market's expansion, however, is the scarcity of skilled pathologists available to manage the escalating diagnostic requirements. This shortage of specialized personnel limits the operational capabilities of laboratories, resulting in delayed result reporting, which can negatively affect patient outcomes. Therefore, the restricted availability of these expert professionals acts as a key impediment that could hinder the global scalability of anatomic pathology services.

Market Driver

The primary driver behind the anatomic pathology market's expansion is the escalating worldwide occurrence of cancer and other chronic diseases, which inherently increases the need for diagnostic procedures. As more complex cancer cases emerge, laboratories are under pressure to efficiently process tissue samples while ensuring high diagnostic accuracy crucial for effective treatment planning. This demand is intensified by the imperative for precise tumor staging and grading, which are essential for guiding advanced therapeutic interventions. The World Health Organization's International Agency for Research on Cancer reported in February 2024 that the global cancer burden reached approximately 20 million new cases in 2022, with a projected 77% increase by 2050, highlighting this pressing need.

Concurrently, the adoption of artificial intelligence (AI) and digital pathology solutions is revolutionizing laboratory operations, improving both workflow efficiency and diagnostic accuracy. Through the digitization of glass slides and the application of machine learning algorithms, pathologists can automate routine tasks, achieve more precise quantification of biomarkers, and alleviate the operational strain caused by workforce shortages. This technological evolution is fostering substantial industry consolidation and investment, focused on scaling digital capabilities throughout healthcare systems. For example, Roche expanded its digital pathology ecosystem in September 2024 by incorporating over 20 advanced AI algorithms from eight partners to aid cancer diagnosis. Similarly, in May 2024, Quest Diagnostics acquired specific assets from PathAI Diagnostics, signaling a broader trend toward tech-enabled services aimed at accelerating AI adoption across its pathology network.

Market Challenge

The foremost challenge impeding the expansion of the Global Anatomic Pathology Market is the severe dearth of qualified pathologists. This insufficient workforce creates a critical bottleneck within the diagnostic process, directly limiting the number of specimens laboratories can efficiently handle. With the increasing demand for biopsy procedures and intricate disease analyses, the lack of adequate specialized personnel compels current staff to work beyond their sustainable capacity. This limitation invariably causes delays in test results and curtails the capacity of pathology services to scale operations to satisfy worldwide requirements, consequently hindering revenue growth and market development initiatives.

Recent industry figures underscore the extent of this operational pressure. The Royal College of Pathologists reported in 2025 that 60% of consultants were working past their contracted hours to manage the growing clinical workload and fill staff vacancies. This dependence on an overstretched workforce emphasizes the gravity of the imbalance between supply and demand. As a result, laboratories cannot fully leverage the increasing diagnostic needs, given that the scarcity of experts impedes the seamless integration of larger caseloads and restricts overall market advancement.

Market Trends

The growing adoption of companion diagnostics for precision medicine is fundamentally reshaping the anatomic pathology market, steering it from traditional morphological diagnosis toward molecular-guided therapeutic choices. As pharmaceutical firms increasingly develop targeted therapies alongside specific diagnostic assays, pathology laboratories are required to implement sophisticated testing protocols capable of precisely identifying patients who qualify for these treatments. This trend is directly supported by the strong pipeline of precision medicines, all of which necessitate validated biomarkers for their prescription. The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, signifying a notable rise and underscoring the increasing dependence on integrated diagnostic-therapeutic pairings in clinical practice.

Concurrently, the amalgamation of molecular and anatomic pathology diagnostics is prompting the incorporation of comprehensive genomic profiling into standard tissue-based workflows. Pathology laboratories are advancing beyond testing for single analytes, embracing next-generation sequencing platforms that can analyze hundreds of genes from a single biopsy. This approach streamlines the diagnostic process and preserves valuable tissue samples. Such integration allows pathologists to offer a more complete understanding of tumor biology and expedites the provision of actionable insights for intricate oncology cases. Illustrating this transition, Illumina announced in August 2024 that the FDA approved its TruSight Oncology Comprehensive test, which profiles over 500 genes to link patients with solid tumors to suitable targeted therapies.

Key Market Players

• Quest Diagnostics Inc
• Danaher Corporation
• PHC Holdings Corporation
• Laboratory Corporation of America Holdings
• F. Hoffmann-La Roche AG
• Agilent Technologies Inc.
• Cardinal Health Inc.
• Sakura Finetek USA Inc.
• NeoGenomics Laboratories Inc.

Report Scope

In this report, the Global Anatomic Pathology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anatomic Pathology Market, By Type

• Histopathology
• Cytopathology
• Surgical Pathology
• Others

Anatomic Pathology Market, By Technique

• Special Staining
• Immunohistochemistry
• Electron Microscopy
• Genetic Testing
• Others

Anatomic Pathology Market, By Application

• Disease Diagnosis
• Drug Discovery
• Development

Anatomic Pathology Market, By End-User

• Hospitals
• Research Laboratories
• Diagnostic Laboratories
• Others

Anatomic Pathology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anatomic Pathology Market.

Available Customizations:

Global Anatomic Pathology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).